Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.

Liu LL, Zhang MF, Pan YH, Yun JP, Zhang CZ.

Tumour Biol. 2014 Mar;35(3):1763-74. doi: 10.1007/s13277-013-1184-2. Epub 2014 Feb 25.

PMID:
24563371
2.

Overexpression of retinoic acid-induced protein 3 predicts poor prognosis for hepatocellular carcinoma.

Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y.

Clin Transl Oncol. 2014 Jan;16(1):57-63. doi: 10.1007/s12094-013-1040-2. Epub 2013 Apr 30.

PMID:
23632812
3.

Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.

Chen D, Zhao P, Li SQ, Xiao WK, Yin XY, Peng BG, Liang LJ.

Eur J Surg Oncol. 2013 Sep;39(9):974-80. doi: 10.1016/j.ejso.2013.06.018. Epub 2013 Jul 8.

PMID:
23845703
4.

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Personeni N, Rimassa L, Pressiani T, Destro A, Ligorio C, Tronconi MC, Bozzarelli S, Carnaghi C, Di Tommaso L, Giordano L, Roncalli M, Santoro A.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1179-87. doi: 10.1007/s00432-013-1429-x. Epub 2013 Apr 9.

PMID:
23568548
5.

Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.

Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J.

Diagn Pathol. 2012 Apr 19;7:44. doi: 10.1186/1746-1596-7-44.

6.

Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma.

Chen XQ, He JR, Wang HY.

Med Oncol. 2012 Sep;29(3):1843-9. doi: 10.1007/s12032-011-0075-x. Epub 2011 Oct 11.

PMID:
21987076
7.

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.

Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, Ross PJ.

Br J Cancer. 2013 Aug 20;109(4):888-90. doi: 10.1038/bjc.2013.410. Epub 2013 Jul 23.

8.

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.

Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N.

Cancer. 2014 Jan 15;120(2):229-37. doi: 10.1002/cncr.28384. Epub 2013 Oct 7.

9.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
10.

Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.

Ou DL, Shyue SK, Lin LI, Feng ZR, Liou JY, Fan HH, Lee BS, Hsu C, Cheng AL.

Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.

11.

Sorafenib in liver function impaired advanced hepatocellular carcinoma.

Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.

Chin Med Sci J. 2014 Mar;29(1):7-14.

PMID:
24698672
12.

Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.

Alsina AE, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N.

Am Surg. 2014 Jul;80(7):680-4.

PMID:
24987900
13.

L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.

Guo X, Xiong L, Zou L, Sun T, Zhang J, Li H, Peng R, Zhao J.

Diagn Pathol. 2012 Aug 13;7:96. doi: 10.1186/1746-1596-7-96.

14.

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9. doi: 10.1097/MEG.0b013e32835d913b.

PMID:
23395995
15.

Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.

Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y.

Mol Cell Biochem. 2013 Jun;378(1-2):99-106. doi: 10.1007/s11010-013-1599-5. Epub 2013 Mar 11.

PMID:
23475171
16.

Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.

Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M.

Hepatology. 2014 Oct;60(4):1264-77. doi: 10.1002/hep.27236. Epub 2014 Aug 25.

PMID:
24849467
17.

Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma.

Kong J, Zhou X, Liu S, Jin T, Piao Y, Liu C, Lin Z.

Int J Clin Exp Pathol. 2014 May 15;7(6):3018-27. eCollection 2014.

18.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
19.

High-level expression of HOXB13 is closely associated with tumor angiogenesis and poor prognosis of hepatocellular carcinoma.

Zhu JY, Sun QK, Wang W, Jia WD.

Int J Clin Exp Pathol. 2014 May 15;7(6):2925-33. eCollection 2014.

20.
Items per page

Supplemental Content

Write to the Help Desk